XML 21 R27.htm IDEA: XBRL DOCUMENT ﻿
v2.3.0.11

Segments of Business and Geographic Areas (Tables) | 6 Months Ended
--- | ---
Jul. 03, 2011
Segments of Business and Geographic Areas [Abstract] |
Sales by segment of business | SALES BY SEGMENT OF BUSINESS
|  | Fiscal Quarters Ended
|  | July 3, |  | July 4, |  | Percent
(Dollars in Millions) |  | 2011 |  | 2010 |  | Change
Consumer |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | $ | 1,339 |  |  | $ | 1,463 |  |  |  | (8.5 | )%
International |  |  | 2,454 |  |  |  | 2,184 |  |  |  | 12.4 |
Total |  |  | 3,793 |  |  |  | 3,647 |  |  |  | 4.0 |
Pharmaceutical |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  |  | 3,239 |  |  |  | 3,110 |  |  |  | 4.1 |
International |  |  | 2,994 |  |  |  | 2,443 |  |  |  | 22.6 |
Total |  |  | 6,233 |  |  |  | 5,553 |  |  |  | 12.2 |
Medical Devices & Diagnostics |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  |  | 2,869 |  |  |  | 2,865 |  |  |  | 0.1 |
International |  |  | 3,702 |  |  |  | 3,265 |  |  |  | 13.4 |
Total |  |  | 6,571 |  |  |  | 6,130 |  |  |  | 7.2 |
Worldwide |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  |  | 7,447 |  |  |  | 7,438 |  |  |  | 0.1 |
International |  |  | 9,150 |  |  |  | 7,892 |  |  |  | 15.9 |
Total |  | $ | 16,597 |  |  | $ | 15,330 |  |  |  | 8.3 | %
|  | Fiscal Six Months Ended
|  | July 3, |  | July 4, |  | Percent
(Dollars in Millions) |  | 2011 |  | 2010 |  | Change
Consumer |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | $ | 2,684 |  |  | $ | 3,023 |  |  |  | (11.2 | )%
International |  |  | 4,791 |  |  |  | 4,390 |  |  |  | 9.1 |
Total |  |  | 7,475 |  |  |  | 7,413 |  |  |  | 0.8 |
Pharmaceutical |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  |  | 6,630 |  |  |  | 6,316 |  |  |  | 5.0 |
International |  |  | 5,662 |  |  |  | 4,875 |  |  |  | 16.1 |
Total |  |  | 12,292 |  |  |  | 11,191 |  |  |  | 9.8 |
Medical Devices & Diagnostics |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  |  | 5,741 |  |  |  | 5,751 |  |  |  | (0.2 | )
International |  |  | 7,262 |  |  |  | 6,606 |  |  |  | 9.9 |
Total |  |  | 13,003 |  |  |  | 12,357 |  |  |  | 5.2 |
Worldwide |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  |  | 15,055 |  |  |  | 15,090 |  |  |  | (0.2 | )
International |  |  | 17,715 |  |  |  | 15,871 |  |  |  | 11.6 |
Total |  | $ | 32,770 |  |  | $ | 30,961 |  |  |  | 5.8 | %
Operating profit by segment of business | OPERATING PROFIT BY SEGMENT OF BUSINESS
|  | Fiscal Quarters Ended
|  | July 3, |  | July 4, |  | Percent
(Dollars in Millions) |  | 2011 |  | 2010 |  | Change
Consumer |  | $ | 549 |  |  | $ | 669 |  |  |  | (17.9 | )%
Pharmaceutical (1) |  |  | 1,714 |  |  |  | 1,833 |  |  |  | (6.5 | )
Medical Devices & Diagnostics (2) |  |  | 1,275 |  |  |  | 1,876 |  |  |  | (32.0 | )
Segments operating profit |  |  | 3,538 |  |  |  | 4,378 |  |  |  | (19.2 | )
Expense not allocated to segments (3) |  |  | (116 | ) |  |  | (158 | ) |  |  |  |
Worldwide income before taxes |  | $ | 3,422 |  |  | $ | 4,220 |  |  |  | (18.9 | )%
|  | Fiscal Six Months Ended
|  | July 3, |  | July 4, |  | Percent
(Dollars in Millions) |  | 2011 |  | 2010 |  | Change
Consumer |  | $ | 1,122 |  |  | $ | 1,454 |  |  |  | (22.8 | )%
Pharmaceutical (1) |  |  | 3,923 |  |  |  | 3,803 |  |  |  | 3.2 |
Medical Devices & Diagnostics (2) |  |  | 3,219 |  |  |  | 5,578 |  |  |  | (42.3 | )
Segments operating profit |  |  | 8,264 |  |  |  | 10,835 |  |  |  | (23.7 | )
Expense not allocated to segments (3) |  |  | (332 | ) |  |  | (335 | ) |  |  |  |
Worldwide income before taxes |  | $ | 7,932 |  |  | $ | 10,500 |  |  |  | (24.5 | )%
(1) |  | Includes litigation expense of $290 million and $540 million recorded in the fiscal second quarter and the first fiscal six months of 2011, respectively. The first fiscal six months of 2011 includes a gain related to the Company’s earlier investment in Crucell recorded in the fiscal first quarter of 2011. The fiscal second quarter and the first fiscal six months of 2010, includes net litigation expense of $115 million and $202 million, respectively.
(2) |  | Includes restructuring expense of $676 million recorded in the fiscal second quarter and first fiscal six months of 2011. Includes litigation expense and additional DePuy ASR™ Hip recall costs of $127 million recorded in the fiscal second quarter of 2011. Includes litigation expense and additional DePuy ASR™ Hip recall costs of $223 million recorded in the first fiscal six months of 2011. Includes net litigation expense of $42 million and income of $1,542 million recorded in the fiscal second quarter and the first fiscal six months of 2010, respectively.
(3) |  | Amounts not allocated to segments include interest income/(expense), non-controlling interests and general corporate income/(expense).
Sales by geographic area | SALES BY GEOGRAPHIC AREA
|  | Fiscal Quarters Ended
|  | July 3, |  | July 4, |  | Percent
(Dollars in Millions) |  | 2011 |  | 2010 |  | Change
U.S. |  | $ | 7,447 |  |  | $ | 7,438 |  |  |  | 0.1 | %
Europe |  |  | 4,543 |  |  |  | 3,832 |  |  |  | 18.6 |
Western Hemisphere, excluding U.S. |  |  | 1,543 |  |  |  | 1,375 |  |  |  | 12.2 |
Asia-Pacific, Africa |  |  | 3,064 |  |  |  | 2,685 |  |  |  | 14.1 |
Total |  | $ | 16,597 |  |  | $ | 15,330 |  |  |  | 8.3 | %
|  | Fiscal Six Months Ended
|  | July 3, |  | July 4, |  | Percent
(Dollars in Millions) |  | 2011 |  | 2010 |  | Change
U.S. |  | $ | 15,055 |  |  | $ | 15,090 |  |  |  | (0.2 | )%
Europe |  |  | 8,726 |  |  |  | 7,934 |  |  |  | 10.0 |
Western Hemisphere, excluding U.S. |  |  | 2,979 |  |  |  | 2,655 |  |  |  | 12.2 |
Asia-Pacific, Africa |  |  | 6,010 |  |  |  | 5,282 |  |  |  | 13.8 |
Total |  | $ | 32,770 |  |  | $ | 30,961 |  |  |  | 5.8 | %

X
- Definition Tabular disclosure of sale by geographic area. + Details
Name: | jnj_SaleByGeographicAreaTableTextBlock
Namespace Prefix: | jnj
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sales by segment of business. + Details
Name: | jnj_SalesBySegmentOfBusinessTableTextBlock
Namespace Prefix: | jnj
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8721-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8736-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 131 -Paragraph 27, 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6905597&loc=d3e13816-109267 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8813-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration